Display Settings:

Format

Send to:

Choose Destination
    Cancer Res. 2011 May 1;71(9):3182-8. Epub 2011 Apr 26.

    STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma.

    Source

    Department of Molecular Medicine, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. ascuto@coh.org

    Abstract

    Persistent STAT3 signaling contributes to malignant progression in many diverse types of human cancer. STAT3 is constitutively active in activated B-cell (ABC)-like diffuse large B-cell lymphomas (DLBCL), a class of nongerminal center derived DLBCL cells for which existing therapy is weakly effective. In this report, we provide a preclinical proof of concept that STAT3 is an effective molecular target for ABC-like DLBCL therapy. Direct inhibition of STAT3 with short hairpin RNA suppressed the growth of human ABC-like DLBCL in mouse models in a manner associated with apoptosis, repression of STAT3 target genes, and inhibition of a tumor-promoting microenvironment. Together, these results suggest that STAT3 is essential to maintain the pathophysiology of ABC-like DLBCL and therefore that STAT3 inhibition may offer a promising approach in its therapy.

    PMID:
    21521803
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC3085657
    Free PMC Article

    Images from this publication.See all images (4) Free text

    Figure 2
    Figure 4
    Figure 1
    Figure 3

      Supplemental Content

      Icon for HighWire Press Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk